司美格鲁肽陷与国产GLP-1药物的减重数据之争

每日经济新闻
Jun 11

2026年6月9日,第86届美国糖尿病协会年会(以下简称ADA)落下帷幕。每年,头部药企都会在这场糖尿病与代谢疾病领域的顶级学术大会上亮相,披露公司在研药物的最新临床数据。  本届大会的最大看点当属辉瑞与诺和诺德围绕GLP-1(胰高血糖素样肽-1)类药物展开的交锋。  6月8日,辉瑞发布了一项Ⅱ期临床研究数据,显示埃诺格鲁肽在多个减重指标上优于诺和诺德的司美格鲁肽;当天,诺和诺德对此迅速发声,称该...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10